Evidence map›Paper›PMID 36230486›Full record

ArticleCancers2022

Evaluation of Blood Soluble CD26 as a Complementary Biomarker for Colorectal Cancer Screening Programs.

Loretta De Chiara, Leticia Barcia-Castro, María Gallardo-Gómez, María Páez de la Cadena, Vicenta S Martínez-Zorzano, Francisco J Rodríguez-Berrocal, Luis Bujanda, Ane Etxart, Antoni Castells, Francesc Balaguer and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Improving colorectal cancer screening programs.World journal of gastroenterology · 2024
    Article
  4. CD26 and Cancer.Cancers · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 1 country.

Loretta De ChiaraDepartment of Biochemistry, Genetics and Immunology, Universidade de Vigo, 36210 Vigo, Spain.ORCID 0000-0001-7700-6417
Leticia Barcia-CastroDepartment of Biochemistry, Genetics and Immunology, Universidade de Vigo, 36210 Vigo, Spain.
María Gallardo-GómezDepartment of Biochemistry, Genetics and Immunology, Universidade de Vigo, 36210 Vigo, Spain.ORCID 0000-0002-4856-9322
María Páez de la CadenaDepartment of Biochemistry, Genetics and Immunology, Universidade de Vigo, 36210 Vigo, Spain.ORCID 0000-0002-8317-8861
Vicenta S Martínez-ZorzanoDepartment of Biochemistry, Genetics and Immunology, Universidade de Vigo, 36210 Vigo, Spain.
Francisco J Rodríguez-BerrocalDepartment of Biochemistry, Genetics and Immunology, Universidade de Vigo, 36210 Vigo, Spain.
Luis BujandaDepartment of Gastroenterology, Biodonostia Health Research Institute, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Universidad del País Vasco (UPV/EHU), 20014 San Sebastián, Spain.
Ane EtxartDepartment of Surgery, Hospital Universitario Donostia, 20014 San Sebastián, Spain.
Antoni CastellsGastroenterology Department, Hospital Clinic, IDIBAPS, CIBERehd, University of Barcelona, 08036 Barcelona, Spain.
Francesc BalaguerGastroenterology Department, Hospital Clinic, IDIBAPS, CIBERehd, University of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0002-0206-0539
Rodrigo JoverDepartment of Gastroenterology, Hospital General Universitario de Alicante, 03010 Alicante, Spain.
Joaquín CubiellaDepartment of Gastroenterology, Complexo Hospitalario Universitario de Ourense, CIBERehd, 32005 Ourense, Spain.ORCID 0000-0002-9994-4831
Oscar J CorderoDepartment of Biochemistry and Molecular Biology, CIBUS Building, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.ORCID 0000-0003-1026-124X
Universidade de Vigo · ESHospital Clínic de Barcelona · ESBiogipuzkoa Health Research Institute · ESCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ESGalicia Sur Biomedical Foundation · ESHospital General Universitario de Alicante Doctor Balmis · ESUniversidade de Santiago de Compostela · ESUniversity of the Basque Country · ES

Funding

Asociación Española Contra el Cáncer GCB13131592CASTInstituto de Salud Carlos III PI15/02007Xunta de Galicia ED431G/02
6 · The paper itself

Abstract

Fecal hemoglobin immunodetection (FIT) in combination with endoscopy has been implemented to reduce mortality from colorectal cancer (CRC), although there are issues that can be improved in relation to participation rates. We studied whether the blood biomarker soluble-CD26 (sCD26), related at least in part to the immune system and inflammation, and/or its dipeptidyl peptidase enzyme activity (DPP4), could help reduce false positives. In a cohort of 1703 individuals who underwent colonoscopy and had a serum sample, sCD26 and DPP4 activity showed statistically significant differences regarding sex and age. According to the colonoscopy findings, sCD26 and DPP4 activity progressively decreased in advanced adenomas and CRC, with statistically significant differences, even between both groups; 918 of them had a FIT result (

Indexed as

advanced adenomasblood testcolorectal cancerDPP4endoscopyFITsoluble CD26

Identifiers

PMID36230486
PMCPMC9559671
OpenAlexW4296466614

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.